摘要
目的评价头孢哌酮／舒巴坦治疗重症下呼吸道医院感染临床疗效及安全性，并评价微生物学疗效。方法采用回顾性研究分析方法，分析2002年3月～2005年3月我院呼吸科重症监护室，56例重症下呼吸道医院感染使用头孢哌酮／舒巴坦治疗的资料。结果头孢哌酮／舒巴坦总有效率达83．9％，细菌清除率为92．2％，细菌产酶率为60．8％，头孢哌酮／舒巴坦药物敏感率88．2％，未见不良反应。结论头孢哌酮／舒巴坦是一种抗菌谱广、疗效显著、副作用少的抗菌药物，特别适用于重症下呼吸道医院感染的疾病治疗。
OBJECTIVE To investigate the clinical and bacterial efficacy and safety of cefoperazone/sulbactam （Sulperazone） on severe nosocomial lower respiratory infections. METHODS The clinical materials in the treatment of severe nosocomical lower respiratory infections from Mar 2002 to Mar 2005 were analyzed retrospectively. RESULTS The overall clinical efficacy rate of Sulperazone was 83.9%, the bacterial eradication rate was 92 %, The sensitivity rate to Sulperazone was 88.2%. There was no adverse reaction in the observation. CONCLUSIONS Sulperazone is effective and safe in the treatment of severe nosocomial lower respiratory infection.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2006年第4期438-439,共2页
Chinese Journal of Nosocomiology
关键词
头孢哌酮/舒巴坦
下呼吸道
医院感染
Cefoperazone/sulbactam
Lower respiratory tract
Nosocomial infections
